Dr Mark Kris highlights a recent study on osimertinib in NSCLC and outlines the best approaches for treatment beyond progression.
Accelerated repopulation is a main reason for locoregional failure after fractionated radiotherapy for head and neck squamous cell carcinoma (HNSCC). Epidermal growth factor receptor (EGFR) is a key ...
“We postulate that these observations may provide novel opportunities for therapeutic interventions for EGFR driven cancers.” “We postulate that BUB1 helps in the formation and stabilization of EGFR ...
Rybrevant Faspro is a subcutaneous co-formulation of amivantamab, a bispecific EGFR-directed and MET receptor-directed antibody, and hyaluronidase.
Subcutaneous (SC) amivantamab reduces administration from hours to minutes, with efficacy and safety consistent with intravenous (IV) amivantamab1,2,3,4,5 SC amivantamab is now authorised across all ...
February 2026 coverage highlighted combination EGFR therapy guidance, chemo-free treatment options, biomarker testing and ...
Topline global pivotal Phase 3 data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC expected mid-2026Global pivotal Phase 3 ...
The OriGAMI-4 trial reveals subcutaneous Rybrevant's 45% response rate in metastatic head and neck cancer patients after ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results